TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05950529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract
Description: Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor
Description: Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge control (sorbitol only)
Description: Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.

Intervention type: OTHER
Group type: OTHER
Intervention: No product
Description: no product
Study: NCT01472666

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High content of MC-SFA
Description: 12 weeks dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 12 weeks dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low content of MC-SFA
Description: 12 weeks dietary intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: 12 weeks dietary intervention
Study: NCT00690573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
Study: NCT04314115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Brief intervention in mindfulness, of individual type, of four sessions of sixty minutes per week, in addition to individual tasks, according to protocol of brief intervention in developed mindfulness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Brief systemic therapy intervention, of four weekly sessions of sixty minutes, with individual tasks and assignments, according to the protocol designed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy and positive psychology
Description: Brief intervention of traditional cognitive behavioral therapy with elements of positive psychology, of four weekly sessions of sixty minutes, with individual assignments and assignments, according to the protocol designed.
Study: NCT02583165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1873
Description: Subjects will receive MEDI1873 by intravenous administration
Study: NCT01084824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen and cantharidin
Description: Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liquid nitrogen and topical placebo
Description: Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
Study: NCT04504292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUPREP Bowel Prep Kit
Description: Bowel prep prior to colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely Oral Product
Description: Bowel prep prior to colonoscopy
Study: NCT02226380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
Study: NCT01899417

Intervention type: DEVICE
Intervention: ConforMIS iTotal® Knee Replacement
Description: Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.

Intervention type: DEVICE
Intervention: ConforMIS iTotal® Knee Replacement
Description: Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
Study: NCT02208518

Intervention type: PROCEDURE
Intervention: endoscopy ultrasound elastography
Description: During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software

Intervention type: DEVICE
Intervention: EUS-elastography
Study: NCT00314262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib & Celecoxib
Description: Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months.
Study: NCT01283282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg PO qday for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg PO qday for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo PO qday for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo PO qday for 6 weeks
Study: NCT00096031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
Study: NCT01821391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDL-PDT
Description: Metvix natural daylight photodynamic therapy
Study: NCT01973296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED to home care transition
Description: The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
Study: NCT01821391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDL-PDT
Description: Metvix natural daylight photodynamic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: c-PDT
Description: Metvix conventional photodynamic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo c-PDT
Description: Metvix placebo conventional photodynamic therapy
Study: NCT03371602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multi-organ sampling
Description: a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
Study: NCT04080362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitralStitch
Description: With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
Study: NCT00682006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine
Description: 4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand washing Soap
Description: Hand washing soap was provided to Mothers through TBAs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Chlorhexidine
Description: 4% Chlorhexidine was provided to be applied by Mothers through TBAs.
Study: NCT02945566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard TME surgery
Description: Total mesorectal excision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long course concurrent chemoradiation with capecitabine and radiotherapy
Description: Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
Study: NCT01429194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACE Stapler
Description: The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
Study: NCT00206700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Open Label, 8 week cycle
Study: NCT01077908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cellular Therapy
Description: CMV-specific T-cells, single infusion at 27 days post-HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best available antiviral drug therapy
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available antiviral drug therapy
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Study: NCT00495573

Intervention type: DRUG
Intervention: acyclovir
Description: 400 mg acyclovir, orally three times a day for 5 days
Study: NCT02197819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sling
Study: NCT01590628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord
Description: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
Study: NCT00083226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV
Study: NCT02197819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Rotation Brace
Study: NCT03234543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Remote ischemic conditioning
Description: Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
Study: NCT00684281

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological and neuropsychological consultation, MRI
Description: Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
Study: NCT00083226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT00684281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA
Description: Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
Study: NCT00795262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinapril (Accupril) plus Alpha Lipoic Acid
Description: Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: accupril, placebo
Description: accupril 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: accupril, alpha lipoic acid
Description: accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
Study: NCT02937727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3T MRI compatible and LFP recordable G106R of Beijing Pins medical.
Study: NCT03573466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
Study: NCT00004578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 150 mg, every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 150 mg, every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 40 mg every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 40 mg every 12 hours
Study: NCT03022747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is added to standard oral 6-mercaptopurine and methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Oral 6-mercaptopurine and methotrexate
Study: NCT00165035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar Paclitaxel Drug Eluting Coronary Stent System
Description: Drug eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Description: Drug eluting stent
Study: NCT01942551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Study: NCT00538616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
Study: NCT02349802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auto-injector with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syringe with exenatide suspension
Description: A flexible study design to accommodate multiple cohorts.
Study: NCT03301350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study: NCT03469713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab).
Study: NCT05687240

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong/Tai Chi
Description: Participants will engage in 8 weeks of gentle movement/mindfulness videos provided in a daily text prompt, asking that this be practices most days of the week. A choice of practice video links will be provided, ranging from 10-30 minutes in length, and later confirmation texts will be employed to document if practiced, and what length was chosen.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Randomized participants will be coached to practice a breathing technique that focuses attention on the sensations in the heart area, slowing and deepening the breath, and activating through memory or imagery a positive emotion. This practice is used along with a feedback device that provides information on achievement of the heart rate variability target, coherence that represents a neurocardiac state associated with vagal tone, or balance.
Study: NCT01746225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
Study: NCT04393168

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lymphatic clearance measurement
Description: The indocyanine green in 5% human albumin solution (tracer) (50 μL) will be injected intradermally in both forearms or both lower legs using MicronJet600 microneedles paying attention to the contralateral symmetry of the injections. The signal at the injection sites will be measured over time using a hand-held portable device LymphMeter 1.0 for the total duration of 3 h. In the first hour, the signal will be measured every 15 minutes followed by measurements every half an hour. Immediately after injection (t=0 h), 1.5 h and 3 h after injection the skin area occupied by the tracer will be measured using a standard near-infrared camera, Fluobeam. The dermal reaction at the injection site will be assessed by observations for presence of redness/erythema and measuring its extent according to the needs. The patient will be constantly observed for the signs of allergic reactions, skin irritations or intolerances.
Study: NCT02168218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7-day overfeeding
Description: 7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day overfeeding
Description: 7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
Study: NCT02969356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSC
Description: The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
Study: NCT00769912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% N2O- 50%O2 mixture
Description: 50% N2O- 50%O2 mixture administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (air)
Description: Placebo administration during the intervention